Garcia-Sanz, R., Sureda, A., de la Cruz, F., Canales, M., Gonzalez, A. P., Pinana, J. L., Rodriguez, A., Gutierrez, A., Domingo-Domenech, E., Sanchez-Gonzalez, B., Rodriguez, G., Lopez, J., Moreno, M., Rodriguez-Salazar, M. J., Jimenez-Cabrera, S., Caballero, M. D., & Martinez, C. (2019). brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group). Annals of oncology, 30, 612–620. http://access.bl.uk/ark:/81055/vdc_100094045739.0x000040